New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
08:44 EDTACT, FRXActavis shares should be bought ahead of guidance, says Sterne Agee
After reevaluating its assumptions regarding the synergies that Actavis (ACT) can generate from its acquisition of Forest Labs (FRX), Sterne Agee raised its price target on Actavis to $250 from $230. The firm recommends buying Actavis ahead of guidance for the combined company ,which the firm expects to be provided in July. Sterne Agee keeps a Buy rating on Actavis.
News For ACT;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
16:18 EDTACTActavis, Durata announce FTC grants early termination of HSR Act
Actavis (ACT) and Durata Therapeutics (DRTX) announced that the FTC has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Actavis' pending acquisition of Durata. The early termination of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Both companies expect the transaction to be completed in Q4.
October 30, 2014
09:39 EDTACTPerrigo in exclusive talks to buy Omega Pharma, Bloomberg says
Subscribe for More Information
09:18 EDTACTPerrigo in exclusive talks to buy Omega Pharma, Bloomberg says
Subscribe for More Information
October 27, 2014
15:18 EDTACTEarnings Preview: Pfizer looks to new products to offset generic competition
Subscribe for More Information
10:36 EDTACTAllergan delivers earnings beat, says willing to consider higher Valeant bid
Subscribe for More Information
October 23, 2014
18:18 EDTACTGlenview Capital acquires stake in Actavis, Bloomberg reports
Subscribe for More Information
08:10 EDTACTActavis confirms appeals court upholds Lo Loestrin Fe patent
Subscribe for More Information
October 22, 2014
08:38 EDTACTActavis signs option to acquire Rhythm Health
Subscribe for More Information
October 21, 2014
06:44 EDTACTActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information
October 20, 2014
18:51 EDTACTOn The Fly: After Hours Movers
Subscribe for More Information
06:28 EDTACTAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 17, 2014
09:47 EDTACTValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:45 EDTACTAllergan not in deal talks with Actavis, CNBC reports

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use